CASE: We report a case of simultaneous methemoglobinemia and hemolytic anemia, probably related to the use of rasburicase, in a child starting treatment for acute lymphoblastic leukemia (ALL). In addition, the patient developed symptoms of pancreatitis. All complications resolved after 3 days of supportive therapy. CONCLUSION: Although usually well tolerated in pediatrics, physicians prescribing rasburicase should be aware of these possible life-threatening adverse reactions.
CASE: We report a case of simultaneous methemoglobinemia and hemolytic anemia, probably related to the use of rasburicase, in a child starting treatment for acute lymphoblastic leukemia (ALL). In addition, the patient developed symptoms of pancreatitis. All complications resolved after 3 days of supportive therapy. CONCLUSION: Although usually well tolerated in pediatrics, physicians prescribing rasburicase should be aware of these possible life-threatening adverse reactions.
Authors: C H Pui; H H Mahmoud; J M Wiley; G M Woods; G Leverger; B Camitta; C Hastings; S M Blaney; M V Relling; G H Reaman Journal: J Clin Oncol Date: 2001-02-01 Impact factor: 44.544
Authors: S C Goldman; J S Holcenberg; J Z Finklestein; R Hutchinson; S Kreissman; F L Johnson; C Tou; E Harvey; E Morris; M S Cairo Journal: Blood Date: 2001-05-15 Impact factor: 22.113
Authors: Hui Liu; Juan Long; Peng-Hui Zhang; Kang Li; Jun-Jie Tan; Bin Sun; Jie Yu; Zhi-Guang Tu; Lin Zou Journal: Int J Hematol Date: 2011-04-12 Impact factor: 2.490